empty

Season’s greetings

Researchers are exploring several promising therapeutic avenues for coughs and colds but symptomatic remedies will remain a pharmacy mainstay for some years to come

The sounds of coughing, nose blowing and sneezing are as much a part of winter as Christmas adverts, leaves on the line, and dull, cold, damp weather. 

Coughs are, however, non-specific and can be a side-effect of certain drugs, a consequence of reflux, or a symptom of a serious disease. Now, new guidelines from the European Respiratory Society (ERS) aim to improve the diagnosis and treatment of chronic cough in primary and secondary care.1 

Meanwhile, researchers are uncovering the details of the link between rhinovirus, which causes half to two-thirds of common colds,2 and asthma exacerbations.3 They even seem to be edging closer to the virological holy grail: a treatment for the common cold.

The ERS guidelines on chronic cough point out that 5-10 per cent of adults will experience “pathologically excessive and protracted cough”. Severe chronic cough can cause complications – such as incontinence, syncope and dysphonia (changes in speech) – that may lead to social isolation, depression and relationship difficulties.1 

It is important to be alert for some causes of chronic cough. The guidelines note, for example, that gastro-oesophageal reflux and aspiration can cause many signs and symptoms associated with chronic cough, such as voice and taste changes, and nasal complaints. Aspiration can cause or predispose to bronchitis, bronchiectasis and asthmatic cough.1 

Pharmacy teams also need to watch for medicines that can cause chronic cough. 

Angiotensin-converting enzyme (ACE) inhibitors, for example, increase the sensitivity of the cough reflex in most patients.

The ERS guidelines note that about 15 per cent of patients taking ACE inhibitors develop chronic cough, which can emerge at any time during treatment. The guidelines point out that “angiotensin II antagonists do not affect the cough reflex”, while some drugs, including bisphosphonates and calcium channel antagonists, which worsen pre-existing reflux disease, can increase cough.1 

The guidelines also note that most adults with chronic cough as their main complaint report an “exquisite sensitivity” to certain inhaled irritants, such as perfumes, bleach and cold air. These irritate the throat and produce an urge to cough. This common clinical presentation suggests a heightened sensitivity of the neuronal pathways that mediate cough underlie the symptoms. 

In addition, the guidelines highlight chronic cough’s “unique epidemiology”: two-thirds of patients are female and prevalence peaks in the 50s and 60s. As a result, ‘cough hypersensitivity syndrome’ is emerging as a distinct diagnosis.1 

Key facts

  • New guidelines from the European Respiratory Society aim to improve the diagnosis and treatment of chronic cough 
  • Research into the link between rhinovirus and asthma exacerbations has helped identify possible treatments
  • Several studies are assessing potential rhinovirus vaccines.

Asthma and the common cold

Cough is, of course, a common symptom of asthma. Indeed, patients with cough-variant asthma present with cough as their sole symptom. Bronchodilators and anti-inflammatories alleviate cough-variant asthma.1 With respiratory viral infections the most common asthma trigger, research is now uncovering the details of the link between rhinovirus and asthma exacerbations. 

For instance, between 60 and 80 per cent of children treated in emergency departments for asthma exacerbations have concomitant rhinovirus infections. During one study, researchers exposed people taking inhaled steroids to control their asthma to a strain of rhinovirus. Their asthma worsened, on average, 2.1 days after developing cold symptoms and beta-agonist use rose. 

Lung function did not change after rhinovirus inoculation3 – but lung function only poorly predicts asthma symptoms. One recent study, for example, showed a “weak and statistically insignificant association” between forced expiratory volume in one second as a percentage of predicted and scores on the Asthma Control Questionnaire.4 

Research into the intimate link between rhinovirus and asthma exacerbations helps identify possible treatments

To trigger an exacerbation, the person with asthma also seems to need to encounter an allergen to which they are highly sensitive. In one study, the risk of an exacerbation increased 30-fold in people with asthma who showed raised levels of IgE – the antibodies that defend against parasitic worms and cause atopic disease – to dust mite when they were also exposed to rhinovirus. In addition, people with asthma can be genetically predisposed to developing exacerbations triggered by rhinovirus.3 

Research into the intimate link between rhinovirus and asthma exacerbations helped identify possible treatments. For instance, targeting IgE and certain cytokines (such as interleukin 13, 25 and 33) seem to reduce the risk of asthma exacerbations triggered by rhinovirus.3 Hopefully, in a few years, we will be able to better treat this perennial problem. In the meantime, it is worth reminding people with asthma to be cautious in the winter.

More pharmacists in Wales to offer sore throat service

Four hundred community pharmacists across Wales are being trained to offer a sore throat test-and-treat service to help ease the pressure on health resources.

The move follows the commissioning of the service in 58 pharmacies within Cwm Taf Morgannwg University Health Board and Betsi Cadwaladr University Health Board in November 2018. 

During this pilot, 3,655 consultations were recorded and there was a significant level of positive feedback from service users. The aim now is to roll out the service across all 716 community pharmacies in Wales. 

From April 2020, Health Education and Improvement Wales (HEIW) will develop a training plan for the remaining 1,000 community pharmacists to support this.

Each year a GP, on average, will see around 120 patients with acute pharyngitis.1 The sore throat test-and-treat service is an additional service within the Choose Pharmacy suite of patient services offered from community pharmacy. Pharmacists assess patients’ symptoms, examine the throat and undertake a simple swab test for those patients with symptoms that suggest they may have a bacterial infection. Test results are available in minutes. The pharmacist and patient then discuss the results of the test, agreeing the best treatment and management of symptoms.

The impact of the training on pharmacists’ ability to manage acute minor illness effectively will be continually evaluated during 2020.

The Healthier Wales strategy’s ambition is to provide health and social care closer to home, says pharmacy dean, Professor Margaret Allan. “This requires a healthcare workforce that is flexible and responsive to the changing needs of patient services. HEIW recognises that community pharmacists can make a significant contribution to improving the health and well-being of their local communities. 

“Supporting community pharmacists to develop additional clinical skills means they can become part of the multidisciplinary team who can treat acute minor ailments in a more timely manner within patients’ localities.”

Reference

  1. NICE: Respiratory tract infections – antibiotic prescribing. Prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care. 

Common cold cure?

Let us now consider the long-sought treatment for the common cold. Usually, a common cold is a mild, self-limiting nuisance – but rhinovirus can cause more serious ailments including bronchiolitis, otitis media, sinusitis, pneumonia, and exacerbate chronic obstructive pulmonary disease, cystic fibrosis and, as already mentioned, asthma.5 

Developing a vaccine is difficult, partly because of rhinovirus’s diversity. There are at least 160 types of rhinovirus in three species: A, B and C. Most type A and all type B rhinoviruses enter cells by binding to a membrane protein called intercellular adhesion molecule 1 (ICAM-1).5 Other rhinoviruses enter cells using the low-density lipoprotein receptor or a protein called cadherin-related family member 3.5 

Rhinovirus is highly selective: 90 per cent of human rhinovirus serotypes don’t bind to mouse ICAM-1, which means there are few animal models. Moreover, the antigens – the triggers that cause the immune system to mount a protective response – vary widely.2 The RNA polymerase is error prone, resulting in a high natural mutation rate, marked genetic diversity and an increased likelihood of drug resistance.

To be effective, patients would also need to take the antiviral early in the course of the infection. However, several pathogens cause similar symptoms and there is currently no point-of-care diagnostic test for rhinovirus, although investigations are underway.5 

Despite these difficulties, several studies are assessing possible rhinovirus vaccines.2 Antiviral drugs may be another possibility. In some patients, for example, the combination of ribavirin and PEGylated interferon alpha 2-a, used to treat hepatitis C, seems to increase rhinovirus clearance. 

Many experimental antivirals for rhinovirus seem to bind to the capsid, the virus’s protein outer coat, which blocks binding to ICAM-1 and other targets on the cell. New drugs that interfere with rhinovirus binding, entry and replication therefore seem promising, although it is early days.2 Another approach aims to boost the body’s natural antiviral immune responses.5 

While researchers are exploring several promising therapeutic avenues, community pharmacists don’t need to worry about finding alternative winter OTC revenue streams just yet. A vaccine or antiviral drug for rhinovirus is some distance from the clinic for vulnerable people, let alone available to purchase. Symptomatic cold remedies will be a pharmacy mainstay for some years to come.     

Hands are key to transmitting colds and flu.

It's quicker by tube... to catch a cold

New research by Jakemans shows that two-thirds of commuters think public transport is a major cause of winter illnesses, with 41 per cent saying they’ve been coughed on during their commute.    

The study of 2,000 commuters found that four in five experienced a winter illness last year, with over a third saying it is ‘very likely’ this was due to their form of travel. Over half (54 per cent) believe they are more likely to catch a sore throat or cough on public transport than working with children.

Sixty-six per cent say they are worried about catching a sore throat or cough; three in 10 believe travelling on the tube is likely to make them catch a winter illness; while over half said buses increase their chances. This is put down to lack of fresh air, germs on handrails and seats, and being in close proximity to strangers, according to over half of the respondents. 

The findings should come as no surprise as 72 per cent of commuters admit they don’t avoid public transport when they have a winter illness and 60 per cent don’t take a day off work. 

Paying lip service to cold sore treatments

For cold sore sufferers, feeling under the weather may lead to an outbreak of the small blisters that develop on the lips or around the mouth. Cold sores are contagious from the moment tingling is first felt to when the cold sore has completely healed.

Cold sores usually clear up by themselves within seven to 10 days, but many sufferers will want to do something to speed the process along. OTC antiviral creams can ease symptoms and speed up healing time, but to be effective they need to be applied as soon as the first signs of a cold sore appear. Other options available include cold sore patches to protect the skin while it heals and electronic devices that treat cold sores with heat therapy, light or lasers.

References

  1. European Respiratory Journal 2019; DOI:10.1183/13993003.01136-2019
  2. Future Virology 2018; 13:505-518
  3. Immunology and Allergy Clinics of North America 2019; 39:335-344
  4. The Journal of Allergy and Clinical Immunology: In Practice 2019; 7:2319-2325
  5. Chest 2019; 155:1018-1025



This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.